https://www.neurologylive.com/view/rituximab-gmg-treatment-wve-003-positive-hd-incidence-guillian-barr-covid-19-vaccination
0
0
Rituximab as Initial gMG Treatment, WVE-003 Proves Positive in HD, and Incidence of Guillian-Barré After COVID-19 Vaccination - Neurology Live
9/24/22 at 11:09am
Organization
Neurologylive.com
Author
NeurologyLive® Staff
Details
36 words
Summarize
Health Health Conditions Rituximab Initial gMG Treatment Vaccination - Neurology Live Neurology News Network WVE-003 Proves Positive Guillain--Barré Syndrome
Neurology News Network for the week ending September 24, 2022. [WATCH TIME: 4 minutes]
Create an account or login to join the discussion